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Abstract 
The microbiota-gut-brain axis is a complex and dynamic multi-directional ‘communication 
superhighway’ within the body including the central nervous system, the autonomic nervous 
system, the neuroendocrine and neuroimmune systems, the lymphatic system, the enteric 
nervous system and the gastrointestinal microbiota. The mechanisms of communication are 
slowly being unravelled and involve the main systems mentioned along with the by-products 
produced such as neuropeptides, neurotransmitter, hormones and immune modulators. Over 
the last decade increasing evidence points to an essential role of this axis in many fundamental 
neural processes and brain disorders. However, the limited clinical and preclinical studies do 
not clearly delineate a role for gut microbiota in the pathophysiology of pain state. The 
most researched area is in irritable bowel syndrome and in visceral pain studies in animal 
models. However, one cannot overlook the involvement of the microbiota in symptoms 
that are comorbid with chronic pain especially affective disorders. In this review we 
synthesise the available information highlighting the gut microbiota in visceral, 
inflammatory, and neuropathic pain states, including fibromyalgia, migraine, cancer and 
chemotherapy-associated pain. Given its part in many effector systems, there is a clear need 
for more focused investigations on the mechanism of action of the microbiota in human pain 
states, as current treatment strategies are often ineffective or provide limited relief. 
 
The Gut Microbiota: Mechanisms of Action 
The significance of the bi-directional communication between the gut and the brain in health 
and disease has long been appreciated. However, in the past two decades, the microbiota (the 
trillions of microorganisms including bacteria, bacteriophage, archaea, protozoa and fungi that 
live within and on our bodies) has emerged as one of the key regulators of gut-brain function 
throughout the lifespan. It has been determined that many factors can influence the 
establishment of the core microbiota that informs host development across the lifespan 
including infection, mode of birth delivery, use of antibiotic medications, the nature of 
nutritional provision, environmental stressors and host genetics [1]. This in turn has led to the 
appreciation of microbiota-gut-brain communication in a myriad of disorders including 
psychiatric, metabolic, neurodevelopmental, age-related and neurodegenerative disorders [1].  
Studies, largely in animal models, have shown that the microbiota regulates fundamental neural 
processes, from neurogenesis and myelination, to activation of microglia and 
neuroinflammatory processes [2] all of which are implicated in pain processes. Despite this 
there has surprisingly been little focus on the role of the microbiota in the initiation, 
development, maintenance and progression of pain disorders. The microbiota and the brain 
communicate with each other via various routes including the immune and inflammatory 
system, endocrine mechanisms, tryptophan metabolism, enteric and vagus neural 
communication, as well as through microbial metabolites such as short chain fatty acids, 
branched chain amino acids, peptidoglycans as well as many other peptides and secondary 
messenger biomolecules. Indeed, many of these metabolites have been identified in pain 
processing.  
 
Pain types  
Pain is a multimodal experience combining a discriminative sensory component with a 
complex graded emotional response. This physiological survival facility is usually transient or 
rapid (acute pain) and is inherent to all sentient organisms to protect against potential or 
existing tissue damage. Both acute and chronic pain can be debilitating, and can influence one’s 
state of mind and contribute to comorbid symptoms including stress, anxiety and depression, 
which in turn can amplify the psychological intensity of the pain [3]. In this review we focus 
more on chronic pain conditions. Crudely, pain types can be categorised as nociceptive pain, 
inflammatory pain or pathological pain. Nociceptive pain is our classical response to a painful 
stimulus such as a pin-prick, where pain receptors on our extremities sense the stimulus and 
transmit the signal to our brains. vasoactive amines and peptides, eicosanoids, proinflammatory 
cytokines, and acute-phase proteinsthe inflammatory process prevents further tissue damage 
and ultimately results in healing and restoration of tissue function, but prolonged inflammation 
due to infection or tissue damage can be detrimental and painful to the host. Pathological pain 
can be a disease state caused by damage to the nervous system or by its abnormal function 
(examples including neuropathic pain, fibromyalgia, migraine and headache) [4].  
 
Within these categories, the pain can be further sub-characterised as somatic (musculoskeletal, 
skin and deep tissue) or visceral (relating to internal organs). The anatomical pathways and 
signalling mechanisms involved in somatic/musculoskeletal pain and responses to acute 
nociceptive insults and acute inflammatory pain are relatively well defined. However, the 
mechanisms underlying visceral pain, neuropathic pain and chronic pain, and their treatment 
are proving a difficult target for therapeutic intervention.  
 
Pain Pathways 
The perception of pain and discomfort involves complex mechanisms, including molecular and 
cellular transduction mechanisms and neuronal plasticity, that lead to peripheral activation of 
sensory nerves and, at a central level, regulation of thalamic and corticolimbic signalling 
pathways (see Figure 1). Acutely, after an event such as injury, stress or infection  the 
nociceptive information coding for heat (inflammation) or pain, is propagated from the site of 
origin to vagal afferents or through ascending spinal pathways to the brain. Nociceptors in the 
viscera, and in skin and tissue respond to mechanical stimulation such as distension or pressure, 
tissue damage and chemical stimulation because of inflammation, infection or ischaemia.  
However, following prolonged or chronic activation, neurons involved in transmitting 
nociceptive information can also become sensitised or dysfunctional leading to the conductance 
of a painful signal to what should be an innocuous stimulus (neuropathic pain). Dysfunction of 
the pain pathways in the anatomical loci at the site of injury, or neural communication from 
site of injury along the spinal cord to the brain and supraspinal regions involved in descending 
pain facilitation and inhibition may lead to chronic, repeated and often unpredictable bouts of 
pain, and may be the root from which neuropathic pain stems. Thus, by targeting key bioactive 
chemicals or receptor systems on these sensory afferent neurons, or those at supraspinal sites, 
the sensation of all pain types (nociceptive, inflammatory and neuropathic) could be 
significantly ameliorated.  
 
Potential Microbiota-Driven Mechanisms in Pain Regulation 
Locally, the gut contains a number of different receptor types involved in the processing of 
pain response including the transient receptor potential channels, of the vanilloid subtype 
(TRPV) family, proteinase activated receptors, cholecystokinin receptors, serotonin receptors, 
cannabinoid receptors, as well as an array of ion channels including ATP-gated ion channels, 
voltage-gated sodium and calcium channels, and acid-sensing ion channels [5]. Gastrointestinal 
microbiota can activate these receptors directly or indirectly through immune responses [6] at 
the mucosal surface during infection, inflammation and autoimmunity, or via formyl peptides 
and protease release, pH changes, polyunsatturated fatty acid (PUFA) release, short chain fatty 
acid (SCFA) production, neurotransmitter production and hormone secretion [7]. Bacteria have 
also been shown to induce calcium flux and action potentials in nociceptor neurons [8]. 
 
As well as influencing local immune responses at the gut epithelium, microbiota can synthesise 
and release neurotransmitters and SCFAs, regulate steroid and bile acid metabolism, as well as 
influence the release of neuropeptides and hormones from enteroendocrine cells of the 
intestines. Some of these could potentially play a role in pain types such as migraine by 
contributing to vasoconstriction. A recent comprehensive study [9] has also highlighted a 
critical role for gastrointestinal microbiota in central microglia maturation, morphology and 
immunological function - an event that may extrapolate to spinal microglia, but this is as yet 
untested. Given the integrative role of microglia in numerous central processes including 
neuroinflammation, it is plausible that this contribution from the microbiota could influence 
central pain processing. Gastrointestinal microbiota can also stimulate the release of the body’s 
natural pain-suppressing biomolecules including opioids from innate neutrophils and 
monocytes, endocannabinoids from colonic tissue, as well as other pain modulators [10] 
including monoamines. Microbial metabolites can also influence epigenetic mechanisms, by 
altering substrate concentrations or by direct inhitibiton of enzymatic machinery in epigenetic 
pathways [11]. Potentially, these circulating cytokines, chemokines, endocrine messengers and 
microbial by-products can infiltrate the blood and lymphatic systems, or influence neural 
messages carried by the vagal and spinal afferent neurons to impact on centrally, and spinally-
mediated events, to differentially modulate response to nociceptive, inflammatory and 
neuropathic pain types.  
 
Below, we synthesise the evidence for microbiota in pain responding, however the temporal 
profile of microbiota-mediated influence on pain response to acute and chronic pain remains, 
as yet, a critical and unaddressed question. 
 
Evidence for a role of Gastrointestinal Microbiota in Pain Response 
Clinical and preclinical studies investigating the role of microbiota in nociceptive (visceral and 
somatic), inflammatory and neuropathic pain are limited. Much of the clinical evidence for 
gastrointestinal microbiota in pain response has focussed on nociceptive disorders of the gut, 
while preclinical studies incorporate nociceptive, neuropathic and inflammatory pain responses 
throughout the body.  
 
Visceral Pain 
Germ-free mice (reared in an enclosed sterile germ-free environment devoid of any 
microorganisms) were shown to have increased sensitivity to pain in the colorectal distension 
model [12], an animal model of visceral pain. Further evidence for an active role of the gut 
microbiota in pain response is with the use of antibiotics to deplete bacterial load. In naïve 
animals, antibiotic-mediated depletion of gastrointestinal microbiota decreased visceral pain-
related response in mice [13] and rats [14], and early-life exposure to antibiotics predisposed 
animals to visceral sensitivity in adulthood [15]. Recently, the transplantation of faecal matter 
containing the gut microbes (faecal matter transplant, or FMT) from irritable bowel syndrome 
(IBS) patients with characterised by hypersensitivity to colorectal distension was transplanted 
to germ-free rats, and the response to colorectal distension was enhanced in these animals [16], 
again suggesting a role for gut microbes in the manifestation and pathophysiology of the 
disease. 
In humans, FMT and probiotic supplementation have been investigated in visceral pain 
disorders including functional gastrointestinal disorders (FGID’s) such as functional dyspepsia, 
IBS and infant colic - and clinical and preclinical evidence for a role for the gut microbiota in 
visceral pain is synthesised in a recent review [17]. Currently, data on FMT on pain in FGIDs 
are too limited to draw conclusions [18]. In terms of visceral sensitivity to pain in IBS sufferers, 
very few randomised double-blind, placebo-controlled studies have reported a beneficial effect 
of probiotics, or probiotic mixes on symptomology including pain/discomfort, 
distension/bloating, urgency and digestive dysfunction. A role for probiotics in paediatric [19] 
functional gastrointestinal disorders is well reviewed in a recent article reporting modest or 
weak effects on pain intensity or frequency. Clinical studies manipulating the microbiota to 
alleviate symptoms in visceral and/or inflammatory pain associated with myocardial infarction 
(heart attack), dysmenorrhea, appendicitis, bladder pain are lacking, with only one study 
reporting a reduction in pelvic pain with comorbid IBS symptomology following antibiotic 
(rifaximin) treatment [20].   
 
Inflammatory Pain 
One of the first examples linking microbiota to pain demonstrated a lower pain response in 
germ-free mice to externally applied inflammatory mediators to the paw [21], yet further 
studies investigating inflammatory pain response in germ-free or antibiotic-treted animals are 
lacking. In the clinic, FMT is medically accepted as a highly successful procedure for the 
eradication of C. difficile infection and associated symptoms including abdominal pain [22]. A 
recent review [23] and metadata analysis [24] captures the efficacy of microbial based 
treatments including probiotic treatments, and FMT in the treatment of inflammatory bowel 
disease and associated inflammatory pain response. In summary, the efficacy of FMT in the 
treatment of IBD was mixed [25] with studies reporting 20-33% clinical remission in pain in 
ulcerative colitis, reduction in pain index in 50-75%  Crohn’s disease individuals, and mixed 
effects 0-80% in pouchitis. An interesting study investigating the anti-inflammatory effect of 
bacterial exopolysaccharide (high molecular weight polymers that certain bacteria can secrete 
into their local environment to benefit their growth and proliferation), determined that it was 
effective in reducing carrageenan-induced inflammatory pain and mechanical hyperalgesia in 
rats [26]. 
 
Somatic and Neuropathic Pain 
Studies investigating the involvement of gastrointestinal microbiota on somatic pain 
(musculoskeletal, cutaneous (skin) or tissue pain) are also limited. Given the rise in antibiotic 
resistant pathogens in recent years, it is surprising that there is relatively little work on skin 
microbiota and pain response. A recent review focussing on work by Chiu and Woolf highlights 
that skin bacteria are able to interact directly with neurons to cause pain, irrespective of their 
effect on the host inflammatory response [27]. Arthritic pain although clearly linked with 
inflammation is focused on the joints. Despite evidence for a role for microbiota, in particular 
Prevotella copri in untreated new-onset rheumatoid arthritis patients [28-30] and evidence 
from animal studies [31] suggesting activation of autoreactive t-cells in the intestine, human 
studies are only now being undertaken to investigate the effects of FMT in arthritis [32], and 
the limited randomised control trials and relatively low numbers in probiotic studies have not 
yielded any clear consensus as to the efficacy of probiotics in arthritis [33,34].  
In a recent preclinical study it was determined that gastrointestinal microbiota 
contribute to chemotherapy-induced neuropathic pain [35] via TLR4 expressed on 
hematopoietic cells, including macrophages. Germ-free and antibiotic-treated animals had 
lower pain responses than their naïve controls. A clinical study with probiotic treatment 
reported efficacy in pain management in post-chemotherapy abdominal pain in colorectal 
cancer patients [36], an event that is caused by chemotherapy-induced gastrointestinal toxicity 
of the gut microbiome-host immune system [37].  
There are no conclusive studies providing a role for the gastrointestinal microbiota in 
migraine. However, evidence suggests that migraine is associated with gastrointestinal 
disorders [38], and a compositional analysis from oral microbiota in the American gut project 
[39] report that microbes that reduce nitrate, nitrite and nitric oxide (all linked with migraine) 
are higher in migraine sufferers. Clinical studies have reported a moderate reduction in number, 
duration and or intensity of migraine events with probiotic administration [40,41] and much 
further work in this research field is warranted given the ability of microbes to release bioactive 
molecules involved in vasoconstriction and vasodilation. To date, studies investigating the 
effect of microbiota manipulation in the treatment of fibromyalgia, a chronic  
widespread muscle and joint pain disorder, are limited to one study reporting no alleviation of  
pain following probiotic administration [42].    
In a preclinical neuropathic pain model, where the sciatic nerve is ligated to become 
sensitised to previously innocuous pressure, the transfer of microbiota from pain-sensitive 
animals to antibiotic-treated mice conferred a painful phenotype [43], again reinforcing an 
involvement of microbes in pain response. Select probiotics did not alleviate painful stimuli in 
a neuropathic and inflammatory pain model [44]. Only one case report observed a beneficial 
effect of microbiota manipulation in neuropathic pain management, with an improvement in 
diabetic neuropathy being observed following FMT [45]. 
 
 
Conclusions and Future Directions 
With the recent advances in sequencing technologies and the accelerating bioinformatics 
pipelines we are increasingly becoming more aware of the role and functions of the trillions of 
microbes in our gut and how they can contribute to overall health. However, the constitution 
of each individual’s gut commensals is unique, and their relationship with their host physiology 
and genetics will likely in the future lead to personalised medicines for the treatment of many 
disorders including pain.  
 
Currently, the limited clinical and preclinical studies do not delineate a clear role for gut 
microbiota in pain. The best evidence is clearly in visceral pain states both in animal models 
and in irritable bowel syndrome However, one cannot overlook the involvement of the 
microbiota in symptoms that are comorbid with chronic pain especially affective disorders. It 
is also becoming clear that many medications used to manage pain can have direct or indirect 
effects on the microbiota composition [46,47].  
 
There is a clear need for large longitudinal cohort studies analysing the microbiome in almost 
all pain states. This needs to be coulped with longitudinal, placebo-controlled, double-blind 
studies with whole-system analysis and [48] complimentary brain imaging and biomarker 
development to integrate central, peripheral and behavioural alterations before, during and after 
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Figure: 1 Schematic outlining the potential role of gut microbiota in nociceptive, inflammatory and 
neuropathic pain. The microbiota may communicate nociceptive information to the brain via various 
routes including the immune and inflammatory systems, endocrine mechanisms, enteric and vagus 
neural communication, as well as through microbial metabolites such as short chain fatty acids, 
branched chain amino acids, neurotransmitter, peptidoglycans and other peptides and secondary 
messenger biomolecules. Nociceptive signals are propagated via spinal afferent nerves through the 
spinal cord to the brain, while inflammatory or neuropathic nociceptive signals may be communicated 
via vagal signals, or through biomolecules in the lymphatic or circulatory system that can cross the 
blood brain barrier to mediate central pain processing.  
 
ANS: Autonomic nervous system; DC: Dendritic cell; NT: Neurotransmitter; NP: Neuropeptide; SCFA: 
Short-chain fatty acids 
 
 
